secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001104659-24-060893
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome reports Q1 net loss $129.5M; cash $309.7M extends into 2026; AL102 topline data H2 2025
--------------------------------------------------------------------------------

- Net loss of $129.5M ($2.51 diluted EPS) includes $112.0M in IPR&D expenses from AL101/AL102 and IM-1021 acquisitions.
- Cash, cash equivalents and marketable securities $309.7M as of March 31, 2024; runway expected into 2026.
- R&D expense $15.4M; G&A expense $6.0M, including $1.8M stock-based compensation.
- Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected second half 2025.
- IND submissions for IM-1021 (ROR1 ADC) and IM-3050 (FAP-targeted RLT) expected Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/0001104659-24-060893-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924060893/tm2414252d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-060893

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer